Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Wu, Zhi-xian; Chen, Feng-sui; Zhou, Xiao-ling; Huang, Qian; Zhang, Shi-an; Wu, Hai-cong; Cai, Li-rong; Zeng, Zhi-yu; Li, Ying-hui; Li, Dong-liang
• Is Part Of: European journal of gastroenterology & hepatology. Volume 31:Issue 7(2019)
• Publication Date: 2019-07
• Subjects: assisted reproduction -- chronic hepatitis B -- DNA -- telbivudine -- tenofovir; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000001345
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Background: Immune-tolerant chronic hepatitis B (CHB) patients awaiting assisted reproduction (AR) are required to initiate antiviral therapy because of laboratory safety concerns. The antiviral therapy in this group has not been well assessed. We sought to explore the efficacy and safety of the combination therapy (COM) of tenofovir (TDF) and telbivudine (LdT). Patients and methods: In this open-label, randomized, controlled study, we enrolled and randomized hepatitis B virus e-antigen (HBeAg)-positive CHB patients awaiting AR into the study COM group and the control (TDF) group. The COM group received combination therapy of TDF and LdT, and the TDF group received a single treatment of TDF. The patients were followed up for at least 48 weeks. The primary endpoint was the proportion of patients with undetectable HBV DNA level at week 12. Results: A total of 121 patients were recruited into the COM group ( n =60) and the TDF group ( n =61). The percentages of patients with undetectable HBV DNA levels were 90.0% (54/60) in the COM group and 67.2% (41/61) ( P =0.002) in the TDF group at week 12; the percentages were 96.6% (58/60) in the COM group and 85.2% (52/61) in the TDF group at week 48 ( P =0.028), respectively. HBeAg seroconversion occurred in 5/60 (8.3%) patients in the COM group and 2/61 (3.3%) patients in the TDF group at week 48 ( P =0.233). Conclusion: TDF and LdT combination therapy shows a rapid antivirological response in immune-tolerant CHB patients awaiting AR, which provide an alternative for this group at AR centers. However, the HBeAg seroconversion rate is unsatisfactory in the short term.